NCT03344705 is a Phase 1 clinical trial of IM19 CAR-T in Hematological Malignancies, sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd..

Who is sponsoring NCT03344705?

NCT03344705 is sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd..

What drugs are being tested in NCT03344705?

Interventions in NCT03344705: IM19 CAR-T, Fludarabine, Cyclophosphamide.

What condition does NCT03344705 study?

NCT03344705 studies Hematological Malignancies.

Is NCT03344705 still recruiting?

NCT03344705 is currently status unknown. Last updated 17 November 2017.

Last reviewed 2017-11-17 · How we verify

NCT03344705

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Evaluation of IM19 Cells

Status unknown Phase 1 Last updated 17 November 2017

What this trial tests

Phase 1 trial testing IM19 CAR-T in Hematological Malignancies in 20 participants. Status unknown.

Timeline

21 August 2017

Primary endpoint
1 October 2020

1 December 2020

Quick facts

Lead sponsor	Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	21 August 2017
Primary completion	1 October 2020
Estimated completion	1 December 2020
Sites	1 location across China

Drugs / interventions tested

IM19 CAR-T — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Hematological Malignancies — all drugs for Hematological Malignancies →

Sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd. — full company profile →

Who can join

Adults 4 to 75, any sex, with Hematological Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

CAR-T cell therapy for hematological malignancies: History, status and promise.
Wang C, Wang J, Che S, Zhao H. · · 2023 · cited 25× · PMID 38027932 · DOI 10.1016/j.heliyon.2023.e21776
Cancer immunotherapy and its facilitation by nanomedicine.
Sui C, Wu H, Li X, Wang Y, et al · · 2024 · cited 12× · PMID 39097732 · DOI 10.1186/s40364-024-00625-6
Chimeric antigen receptor modified T-cells for cancer treatment.
Han X, Wang Y, Han WD. · · 2018 · cited 11× · PMID 30603741 · DOI 10.1016/j.cdtm.2018.08.002

Verify or expand the search:

Other trials of IM19 CAR-T

Trials testing the same drug.

NCT04336501 — Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation · NA · unknown
NCT03173417 — Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T) · Phase 1, PHASE2 · completed
NCT03142646 — Safety and Efficacy Evaluation of IM19 CAR-T Cells · Phase 1, PHASE2 · unknown

Other recruiting trials for Hematological Malignancies

Currently open trials in the same condition.

NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
NCT06584955 — Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies · NA · active not recruiting
NCT06387082 — A Clinical Study of HMPL-506 in Patients With Hematological Malignancies · Phase 1 · recruiting
NCT06150469 — Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies · NA · recruiting
NCT06179511 — Study of AZD9829 in CD123+ Hematological Malignancies · Phase 1, PHASE2 · active not recruiting

Other Beijing Immunochina Medical Science & Technology Co., Ltd. trials

Trials by the same sponsor.

NCT07406984 — Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction · Phase 1 · not yet recruiting
NCT06886919 — Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus · EARLY_PHASE1 · not yet recruiting
NCT06852573 — Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus · Phase 1 · not yet recruiting
NCT06718738 — Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer · Phase 1 · recruiting
NCT06690359 — IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03344705 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Immunochina Medical Science & Technology Co., Ltd.
Last refreshed: 17 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03344705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing